CALGARY, ALBERTA--(Marketwired - July 23, 2014) -

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES OF AMERICA. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAWS.

Triox Limited (TSX VENTURE:TTL.P) (the "Corporation" or "Triox") is pleased to announce that it has entered into an amalgamation agreement dated effective July 2, 2014 (the "Amalgamation Agreement") with a wholly-owned subsidiary of Triox ("Triox Subco") and eQube Technology and Software Inc. ("eQube"), in furtherance of Triox's proposed business combination with eQube (the "Transaction") as previously disclosed in the news release of the Corporation dated April 8, 2014 and available, along with the Amalgamation Agreement, under the Corporation's SEDAR profile at www.sedar.com. It is expected that the Transaction will constitute the "Qualifying Transaction" of Triox as such term is defined in the policies of the TSX Venture Exchange (the "Exchange").

Amalgamation Agreement

Pursuant to the Amalgamation Agreement, Triox Subco and eQube will amalgamate under the Business Corporations Act (Alberta) (the "Amalgamation") to form a new company under the corporate name "eQube Technology and Software Inc." ("Amalco"), and Amalco will carry on the business previously carried on by eQube as a subsidiary of Triox as it exists post-Qualifying Transaction (the "Resulting Issuer").

Immediately prior to the completion of the Amalgamation, Triox will consolidate all of its issued and outstanding ordinary shares ("Triox Shares") and all outstanding options and warrants to purchase Triox Shares on the basis of 3 Triox Shares for every 1 post-consolidation Triox Share (the "Consolidation"). After completion of a concurrent financing and the Consolidation, and at the effective time of the Amalgamation Agreement (the "Effective Time"), the holders of class "A" common shares of eQube ("Class A Shares") will be deemed to have exchanged each Class A Share for 3 post-Consolidation Triox Shares. Each Class A Share held by Triox will then be exchanged for common shares of Amalco ("Amalco Common Shares"), after which the Class A Shares will be cancelled. Also at the Effective Time, the holders of class "F" preferred shares of eQube ("Class F Shares") will be deemed to have exchanged each Class F Share for one preferred share of Amalco, after which the Class F Shares will be cancelled. Triox will receive 1 fully paid and non-assessable Amalco Common Share for each Triox Subco share ("Subco Share") held by Triox, after which all such SubCo Shares shall be cancelled and each holder of Subco Shares (except for Subco Shares held by Triox) shall be deemed to have exchanged such Triox Subco Shares for ordinary shares of the Resulting Issuer ("Resulting Issuer Ordinary Shares") pursuant to the Amalgamation and shall receive 1 fully paid and non-assessable Resulting Issuer Ordinary Share for each Subco Share held by that holder immediately before the Amalgamation. Upon and in consideration for the issuance of the Resulting Issuer Ordinary Shares, in exchange for the Subco Shares, Triox shall receive 1 fully paid and non-assessable Amalco Common Share for each Subco Share that is so exchanged, after which those Subco Shares shall be cancelled. The Corporation will satisfy the transaction price for the eQube Class A Shares and SubCo Shares by issuing in the aggregate a maximum of 28,519,402 Resulting Issuer Ordinary Shares to the holders of eQube Class A Shares and SubCo Shares at a deemed price, on a post-Consolidation basis, of $0.50 per Resulting Issuer Ordinary Share.

Upon completion of the Transaction, it is expected that there will be 32,286,069 issued and outstanding Resulting Issuer Ordinary Shares. Following completion of the Transaction, Amalco will be a subsidiary of the Resulting Issuer and will, as a subsidiary of the Resulting Issuer, carry on the business previously carried on by eQube.

Trading Halt

The ordinary shares of Triox are currently halted from trading and are not expected to resume trading until completion of the Qualifying Transaction.

Additional Information

Completion of the Qualifying Transaction is subject to a number of conditions including, but not limited to, completion of the Amalgamation, satisfactory due diligence by each of the Corporation and eQube, closing conditions customary to transactions of the nature of the Qualifying Transaction, approvals of shareholders, directors, regulators and third parties that may be necessary or desirable, Exchange acceptance and, if required by the Exchange policies, majority of the minority shareholder approval. Where applicable, the Qualifying Transaction cannot close until the required shareholder approvals are obtained and there can be no assurance that the Qualifying Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or filing statement to be prepared in connection with the Qualifying Transaction, any information released or received with respect to the Qualifying Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of a capital pool company should be considered highly speculative.

Cautionary Statements

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the proposal to complete the Qualifying Transaction and associated transactions, including statements regarding the terms and conditions of the Qualifying Transaction, the Consolidation, and the Amalgamation. The information about eQube contained in the press release has not been independently verified by the Corporation. Although the Corporation believes in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Corporation can give no assurance that they will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may differ materially from those contemplated by these statements depending on, among other things, the risks that the parties will not proceed with the Qualifying Transaction, the Consolidation, the Amalgamation and associated transactions, that the ultimate terms of the Qualifying Transaction, the Consolidation, the Amalgamation and associated transactions will differ from those that currently are contemplated, and that the Qualifying Transaction, the Consolidation, the Amalgamation and associated transactions will not be successfully completed for any reason (including the failure to obtain the required approvals or clearances from regulatory authorities). The terms and conditions of the Qualifying Transaction may change based on the Corporation's due diligence (which is going to be limited as the Corporation intends largely to rely on the due diligence of other parties of the Qualifying Transaction to contain its costs, among other things) and the receipt of tax, corporate and securities law advice for both Triox and eQube. The statements in this press release are made as of the date of this release. The Corporation undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Corporation, eQube, their securities, or their respective financial or operating results (as applicable).

Neither the TSX Venture Exchange, Inc. nor its Regulation Services Provider (as that term is defined in the polices of the TSX Venture Exchange) has in any way passed upon the merits of the Qualifying Transaction and associated transactions and neither of the foregoing entities has in any way approved or disapproved of the contents of this press release.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities of Triox, eQube and Triox Subco have not been and will not be registered under the United States Securities Act of 1933, as amended and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Triox LimitedRobb McNaughtonDirector(403) 232-9689eQube Technology and Software Inc.Kent TongPresident and CEO(780) 414-8890 ext.227

The rising number of users has led to "staggering" growth in the availability of e-cigarettes with around 10 new brands coming to market every month, a second study showed.

Writing in the journal Tobacco Control, researchers from the United States said their findings underlined the size and speed of growth in the market for e-cigarettes, and the need for more research into their potential risks and benefits.

"As e-cigarettes represent an emerging market in which the tobacco industry has extensively invested, it is imperative to identify the population subgroups that are more likely to use them and the subsequent implications this might have on public health," said Constantine Vardavas, a senior research scientist at Harvard School of Public Health who led the study.

"These new findings show that millions - including many young people and smokers trying to quit - are trying e-cigarettes, which underscores the importance of assessing their potential harm or benefits."

E-cigarettes are battery-operated devices designed to deliver a similar nicotine hit and sensory sensation to conventional cigarettes, but without the harmful carcinogens that come from burning tobacco.

They are seen by many as a healthier alternative to cigarettes and as a way to help smokers quit. A group of 53 top scientists warned the World Health Organisation (WHO) last month not to classify and regulate e-cigarettes as tobacco products, arguing that doing so would jeopardise a vital opportunity to reduce smoking-related disease and deaths. [ID:nL6N0OF2E3]

Smoking kills half of all those who do it, giving a death toll of around 6 million people a year, according to the WHO.

The tobacco industry has invested heavily in the rapidly emerging e-cigarette market and some public health experts worry they could be a new route to nicotine addiction and a gateway to cigarette smoking.

A second study published in the same journal on Monday found that the number and type of e-cigarettes available online has soared in the past few years, with around 10 new brands and more than 240 new flavours coming to market every month.

Researchers in that study said the large number of brands and "the variety of flavours (is) staggering" and noted a shift in marketing tactics from promoting them as cigarette substitutes to styling them as nicotine delivery systems offering consumer choice in models and flavours.

In the first study, which sought to gauge perceptions of e-cigarettes and their use across Europe, the researchers analysed data from a survey known as Eurobarometer 2012 which involved more than 26,500 adults from 27 countries in the region.

Respondents were asked if they had ever tried e-cigarettes, and how often; whether they had ever heard of them; and whether they thought they were harmful or not to health.

People who smoked were also asked if they had tried to quit during the previous 12 months, and whether they had used e-cigarettes to do this. And they were asked what factors influenced their choice of cigarette brand.

The results showed that e-cigarette users were more likely to be young - aged 15 to 24 - current smokers of up to 20 cigarettes a day, and to have made at least one attempt to kick their habit over the past year. Would-be quitters over the past year were twice as likely to have tried an e-cigarette as those who had not tried to quit.

Extrapolating the figures to the whole EU population suggests that 29.3 million adults across the 27 countries have tried e-cigarettes, the researchers said.

"Our study's implications are strategically important for European policymakers," they wrote. "On the one hand, quitting tobacco use at an earlier age would substantially benefit individuals and public health. However, the re-normalisation of smoking ... or maintained nicotine addiction may significantly hinder efforts to stop tobacco use."

SAN FRANCISCO and GENEVA, Aug. 1, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has acquired an exclusive option to license the intellectual property surrounding the therapeutic concepts of Dr. Thomas Arendt from the University of Leipzig that were presented at the 3rd Alzheimer's focused Coalition for Concussion Treatment Summit. Under the terms of the agreement, the Company and the University of Leipzig will have 12 months to negotiate a definitive license agreement, and the Company will work with Dr. Arendt to establish a Sponsored Research Agreement to outline the advancement of the therapeutic strategies into human clinical development.

"We are extremely pleased to enter into this agreement that further positions Amarantus within the cell cycle dysregulation field in Alzheimer's disease," said Gerald E. Commissiong, President & CEO of Amarantus. "We believe new concepts and ideas are required to make progress in treating this devastating disorder, and we believe Dr. Arendt's pioneering work that led to LymPro also has therapeutic applications. We look forward to working with the University to execute definitive agreements."

Dr. Arendt has filed international patent applications on the concepts of modulating the expression of P16 in the brains of patients of Alzheimer's disease using gene therapy. P16 is a cell cycle protein that assists in maintaining and nurturing synaptic connections that is hypothesized to be at the root of Alzheimer's pathology. The Company is currently developing an Alzheimer's blood diagnostic LymPro Test® capable of identifying cell cycle dysregulation by harvesting peripheral blood lymphocytes. This option agreement opens the possibility of a targeted therapeutic on those Alzheimer's patients that have tested positive for LymPro.

About Alzheimer's disease

It is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease and over 500,000 patients are diagnosed annually, with nearly one in eight older Americans affected by the disease. Alzheimer's is the third leading cause of death in the United States. The estimated cost of unpaid care in the United States is estimated at over $210 billion annually and the total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. It is estimated that the cost to the United States will exceed $1.4 trillion by 2050.

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready small molecule indicated for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit www.Amarantus.com, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

PR Newswire

BAODING, China, Sept. 22, 2014

BAODING, China, Sept. 22, 2014 /PRNewswire/ -- Yingli Green Energy Holding Company Limited (NYSE: YGE), the largest vertically integrated photovoltaic ("PV") module manufacturer in the world, known as "Yingli Solar," today announced that it will supply over 24 megawatts (MW) of solar PV modules for the Pavana Solar Park, which is the largest solar power plant to break ground in Honduras. The project is owned by Energia Basica S.A. ("ENERBASA"), a Honduran energy company. Sybac Solar, a leading global solar integrator based in the United States, will provide engineering, procurement and construction (EPC) services.

Located in the city of Choluteca in southern Honduras, the Pavana Solar power plant is expected to be the largest solar project to connect to the country's national utility grid. Yingli will deliver nearly 80,000 large-format YGE 72 Cell Series modules to the project site from October through November 2014, and interconnection is expected to take place during the first quarter of 2015. Forecasts indicate that the system will generate approximately 40,000 megawatt-hours annually, which is equivalent to the annual electricity consumption of about 61,000 Honduran citizens.

"Thanks to projects like the Pavana Solar Park, our Central American footprint is growing quickly," noted Mr. Robert Petrina, Managing Director of Yingli Green Energy Americas. "Yingli's strategy in Latin America is to invest in sophisticated local operations and forge deep partnerships with the region's market leaders, including ENERBASA and Sybac Solar. As the pace of solar PV project development and construction accelerates in Latin America, our dedicated local presence has become a powerful differentiator."

"We are thrilled to contribute to Honduras' largest solar project to date, which will help the country reach its goal of meeting sixty percent of domestic electricity demand with renewable resources by 2020," commented Mr. Jeffrey Barnett, Vice President of International Sales of Yingli Green Energy Americas. "Thanks to a robust regulatory framework for renewable energy that includes net energy metering, a feed-in tariff, and tax incentives, Honduras is one of highest potential solar PV markets in Central America."

"We are proud of developing the first utility-scale solar project in Honduras and one of the largest in the region, thanks in part to the financial institutions that support us, to our shareholders that are devoted to investing in Honduras, and to our partnership with Yingli, which allows us to leverage economies of scale to deliver high quality, high value renewable energy solutions to Hondurans," noted Mr. Armando Ayes, ENERBASA´s General Manager. ¨This project demonstrates how our fast-track development model is ideally suited to the Honduran government's strategic renewable energy initiatives. Our group is eager to replicate this model throughout Latin America, and we are actively pursuing opportunities to develop projects using a broad range of renewable energy technologies."

"We have a strong track record of success partnering with Yingli as our key supplier for projects across the Americas, so we trust their dedicated Latin American team to deliver both high-quality products and excellent service," commented Mr. Markus Falz, Chief Executive Officer of Sybac Solar.

"We hope that this groundbreaking project will be the first of many Yingli Solar power plants in Honduras," said Mr. Liansheng Miao, Chairman and Chief Executive Officer of Yingli Green Energy. "By utilizing the region's vast solar potential, projects like the Pavana Solar Park are helping the nation create local jobs, reduce dependence on fossil fuels, and serve as a model for other Central American countries seeking to expand renewable energy generation."

About Yingli Green Energy

Yingli Green Energy Holding Company Limited (NYSE: YGE), known as "Yingli Solar," is the world's largest photovoltaic module manufacturer in terms of production capacity and shipments. Yingli Green Energy's manufacturing covers the photovoltaic value chain from ingot casting and wafering through solar cell production and module assembly. Headquartered in Baoding, China, Yingli Green Energy has more than 30 regional subsidiaries and branch offices and has distributed more than 10,000 MW of PV modules to customers worldwide. For more information, please visit www.yinglisolar.com and join the conversation on Facebook, Twitter and Weibo.

About ENERBASA

ENERBASA is an affiliate of Luz y Fuerza de San Lorenzo S.A. de C.V. (¨LUFUSSA¨), a company which is a key member of a Honduran corporate business group, which include power generation plants with an installed capacity of 581 MW throughout the Central American region. ENERBASA´s sole purpose is the development of the Pavana Solar power plant, however the project is being directed by LUFUSSA´s development team which have a proven track record of over 21 years in the industry. The group´s vision is currently focused on continuing to invest in renewable energy and seeking to develop strategic partnerships in order to actively participate in the consistent growth of photovoltaic and other renewable energy projects in the Latin American Region. For more information, visit www.lufussa.com or send inquiries to enerbasa@deresahn.com.

About Sybac Solar

Sybac Solar develops, engineers, builds, owns, and operates solar PV facilities in the United States and Latin America. Sybac is one of the largest solar integrators in the South East United States and has a proven track record of successful project development.

Sybac Solar was established in 2009 and is headquartered in Orlando, Florida. Sybac Solar retains in-house development, engineering, and construction management teams, minimizing the need to subcontract these services and ensuring a highly efficient development cycle. The company's experienced leadership team emphasizes attention to detail and customer service in all phases of the development process. For more information, visit www.sybacsolar.com.

Safe Harbor Statement

This press release contains forward-looking statements. These statements constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "target" and similar statements. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Yingli Green Energy's control, which may cause Yingli Green Energy's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in Yingli Green Energy's filings with the U.S. Securities and Exchange Commission. Yingli Green Energy does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

For further information about Yingli Green Energy, please contact:

In China

Qing Miao Vice President of Corporate Communications Yingli Green Energy Holding Company Limited Tel: +86 312 8929787 E-mail: ir@yingli.com

In the Americas:

Helena KimballHead of Marketing Yingli Green Energy Americas Inc.Tel: +1-603-591-5812Email: helena.kimball@yingliamericas.com

In Europe:

Rebecca JarschelPublic Affairs & Public Relations DirectorYingli Green Energy International AGTel: +41 (0) 44 567 6143Email: rebecca.jarschel@yinglisolar.ch

Logo - http://www.prnasia.com/sa/2012/04/01/20120401160439160364.jpg

SOURCE Yingli Green Energy Holding Company Limited